Manufacturer: Astra Zeneca

BYDUREON 

Used for: Treatment of Type 2 DM in combination with Metformin, or sulfonylurea, or pioglitazone, or metformin and sulfonylurea, or metformin and pioglirazone, when these, whether combined or alone, are not sufficient to achieve an adequate blood glucose control.

Monotherapy License: No

Insulin License: No

Dose: 2mg once weekly 

Side effects: 

Common: hypoglycaemia (when used with sulfonylurea), nausea, vomiting, bloating, diarrhoea, abdominal pain, constipation, flatulence, headache, dizziness, fatigue, injection site reactions. Uncommon: hair loss, sweating, dehydration, changes in renal function (renal failure).

Renal impairment: Not recommended if Cr clearance is < 50ml/min.

Pregnancy and lactation: Stop before pregnancy, do not use during pregnancy. Do not use while breast feeding.

Contraindications: Allergy to any of the ingredients. In addition to this, in the US, also a past medical history or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Hyperplasia Type 2 (MEN 2). If a patient develops pancreatitis while taking this medication, do not restart the medication after the episode of pancreatitis.